Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Robotic-Assisted Laparoscopic Radical Prostatectomies

August 27th 2012

Prostate Cancer Screening and Early Detection, Part III

August 27th 2012

Prostate Cancer Screening and Early Detection, Part I

August 27th 2012

Prostate Cancer Screening and Early Detection, Part II

August 27th 2012

Researchers Determine Immune Parameters that Lead to Better Survival in Patients who Receive Sipuleucel-T

August 17th 2012

Researchers have determined that patients who received sipuleucel-T (Provenge, Dendreon) developed immune parameters that correlate to improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level to improve survival.

Newly Published Results Show Survival Benefit with Enzalutamide in Prostate Cancer

August 16th 2012

The novel drug enzalutamide (formerly MDV3100) significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Ryan on the Unblinding of the COU-AA-302 Trial

August 13th 2012

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses the Unblinding of the COU-AA-302 Trial

Urology Practice Management Peer Exchange

August 10th 2012

Investigating Large and Small Urology Practice Intricacies

August 10th 2012

Balancing Quality of Care and Costs in Urology Practices

August 10th 2012

Physician Extenders in Urology Practices, Part I

August 10th 2012

Bone Health Programs in Urology Practices, Part II

August 10th 2012

Introduction to Urologists in Cancer Care Peer Exchange

August 10th 2012

Bone Health Programs in Urology Practices, Part I

August 10th 2012

Management of Oncology Care in Urology Practices

August 10th 2012

Physician Extenders in Urology Practices, Part II

August 10th 2012

Study Supporting Lower Threshold on PSA Risk Levels Wins Award

August 6th 2012

Men with a baseline PSA between 1.5 and 4.0 ng/mL faced a 15-fold increase in prostate cancer over a four-year period as compared with men whose baseline PSA levels were

Abiraterone Acetate Significantly Improves PFS in Metastatic Prostate Cancer

August 3rd 2012

An interim analysis of the COU-AA-302 trial investigating the use of abiraterone acetate (Zytiga) in chemotherapy-naÃ¯ve patients with mCRPC showed a trend toward improvement in PFS and OS.

Leading Enzalutamide Investigator Offers Insights Into Pivotal Data

August 1st 2012

Since the phase III AFFIRM trial of enzalutamide was halted after meeting its endpoint of improved OS, physicians have remained hopeful about its potential as a treatment for prostate cancer.

Heat-Shock Protein Inhibitor Delays Disease Progression in Phase II Trial

July 26th 2012

The novel agent OGX-427 delayed disease progression in chemotherapy-naÃ¯ve patients with metastatic castration-resistant prostate cancer, according to the preliminary results.